FV-100: The most potent and selective anti-varicella zoster virus agent reported to date

Antiviral Chemistry and Chemotherapy

Volumn 20, Issue 3, 2010, Pages 107-115

  Migliore, Marco ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; 5' VALYL ESTER; ACICLOVIR; ALKYL ARYL ETHER; ALPHA CYCLODEXTRIN; ANTIVIRUS AGENT; BENZENE DERIVATIVE; BETA CYCLODEXTRIN; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CF 1743; ETHER DERIVATIVE; FLUDARABINE; FLUOROURACIL; FV 100; PYRIMIDINE NUCLEOSIDE DERIVATIVE; SORIVUDINE; UNCLASSIFIED DRUG; VALACICLOVIR; FV-100; PYRIMIDINE NUCLEOSIDE;

BIOASSAY; CHRONIC LYMPHATIC LEUKEMIA; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG UPTAKE; FLUORESCENCE MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VARICELLA ZOSTER VIRUS; GROWTH, DEVELOPMENT AND AGING; HERPES ZOSTER; HUMAN;

ANTIVIRAL AGENTS; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; PYRIMIDINE NUCLEOSIDES;

EID: 77649201225     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1472     Document Type: Review

References (29)

1. Cohen JI, Straus SE. Varicella-zoster virus and its replication. In Knipe DM, Howley PM, Griffin DE, et al. (Editors). Field's Virology. 4th edn. Lippincott Williams & Wilkins 2001; pp. 2707-2730.
2. Stover BH, Bratcher DF. Varicella-zoster virus: infection, control and prevention. Am J Infect Control 1998; 26:369-381.
3. Miwa N, Kurosaki K, Yoshida Y, Kurokawa M, Saito S, Shiraki K. Comparative efficacy of acyclovir and vidarabine on the replication of varicella-zoster virus. Antiviral Res 2005; 65:49-55.
4. Fiddian AP. Antiviral drugs in development for herpes zoster. Scand J Infect Dis Suppl 1996; 100:51-54.
5. Erlich KS. Management of herpes simplex and varicellazoster virus infections. West J Med 1997; 166:211-215.
6. Balzarini J, McGuigan C. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides. Biochim Biophys Acta 2002; 1587:287-295.
7. McGuigan C, Balzarini J. Aryl furano pyrimidines: the most potent and selective anti-VZV agents reported to date. Antiviral Res 2006; 71:149-153.
8. Crisp GT, Flynn BL. Palladium-catalyzed coupling of terminal alkynes with 5-(trifluoromethanesulfonyloxy) pyrimidine. J Org Chem 1993; 58:6614-6619.
9. Robins MJ, Barr PJ. Nucleic-acid related-compounds. 31. Smooth and efficient palladium copper catalyzed coupling of terminal alkynes. Tetrahedron Lett 1981; 22:421-424.
10. McGuigan C, Yarnold C J, Jones G et al. Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. J Med Chem 1999; 42:4479-4484.
11. McGuigan C, Barucki H, Blewett S, et al. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. J Med Chem 2000; 43:4993-4997.
12. Luoni G, McGuigan C, Andrei G, Snoeck R, De Clercq E, Balzarini J. Bicyclic nucleoside inhibitors of varicella-zoster virus: the effect of branching in the p-alkylphenyl side chain. Bioorg Med Chem Lett 2005; 15:3791-3796.
13. McGuigan C, Pathirana R, Snoeck R, Andrei G, De Clercq E, Balzarini J. Discovery of a new family of inhibitors of human cytomegalovirus (HCMV) base upon lipophilic alkyl furano pyrimidine dideoxy nucleosides: action via a novel non-nucleosidic mechanism. J Med Chem 2004; 47:1847-1851.
14. Janeba Z, Balzarini J, Andrei G, Snoeck R, De Clercq E, Robins MJ. Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furoand pyrrolo[2,3-d]pyrimidine nucleosides. J Med Chem 2005; 48:4690-4696.
15. Carangio A, McGuigan C, Andrei G, Snoeck R, De Clercq E, Balzarini J. Bicyclic nucleoside inhibitors of varicella-zoster virus: synthesis and biological evaluation of 2′,3′-dideoxy-3′fluoro and 2′-deoxy-xylo derivatives. Nucleosides Nucleotides Nucleic Acids 2003; 22:935-937.
16. Migliore MD, Zonta N, McGuigan C, et al. Synthesis and antiviral activity of the carbocyclic analgue of the highly potent and selective anti-VZV biciclo furano pyrimidine. J Med Chem 2007; 50:6485-6492.
17. Sienaert R, Naesens L, Brancale A, De Clercq E, McGuigan C, Balzarini J. Specific recognition of the bicyclic pyrimidine nucleoside analogues, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol 2002; 61:249-254.
18. Sienaert R, Andrei G, Snoeck R, De Clercq E, McGuigan C, Balzarini J. Inactivity of the bicyclic pyrimidine nucleoside analogues against simian varicella virus (SVV) does not correlate with their substrate activity for SVV-encoded thymidine kinase. Biochem Biophys Res Commun 2004; 315:877-883.
19. Balzarini J, Sienaert R, Liekens S, Van Kuilenburg A, Carangio A, Esnouf R. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicellazoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Mol Pharmacol 2002; 61:1140-1145.
20. Desgranges C, Razaka G, De Clercq E, Herdewijn P, Balzarini J, Drouillet F. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res 1986; 46:1094-1101.
21. Adak R, Mollwitz B, Migliore M, et al. SAR of alkyloxyphenyl furano pyrimidines: potent and selective anti-VZV agents. Antiviral Res 2006; 70:A66.
22. McGuigan C, Blewett S, Siccardi D, et al. Alkyloxyphenyl furano pyrimidine as potent and selective anti-VZV agents with enhanced water solubility. Antivir Chem Chemother 2002; 13:91-99.
23. McGuigan C, Pathirana R, Migliore M, et al. Preclinical development of the BCNAs: the most potent anti-VZV agents reported to date. Antiviral Res 2006; 70:A31.
24. Blewett S, McGuigan C, Baricki H, et al. Bicyclic furo pyrimidine nucleosides with aryloxyphenyl and halophenyl substituted side chains as potent and selective varicellazoster virus inhibitors. Nucleosides Nucleotides Nucleic Acids 2001; 20:1063-1066.
25. McGuigan C, Pathirana R, Migliore M, et al. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J Antimicrob Chemother 2007; 60:1316-1330.
26. Soul Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute biovalability and metabolic disposition of valacyclovir, the l-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995; 39:2759-2764.
27. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343:1750-1757.
28. Simpson JC, Griffiths G, Wessling-Resnick M. A role for the small GTPase Rab21 in the early endocytic pathway. J Cell Sci 2004; 117:6297-6311.
29. Matson M, Atiee G, Pentikis H, Boehlecke B, Wenzel E, Morris A. A study of the safety and pharmacokinetics of single and multiple doses of FV-100 in subjects 65 years and over. Antiviral Res 2009; 82:A49.